| Literature DB >> 29872305 |
Omar F Khabour1,2, Karem H Alzoubi3, Abdul Samad Firoz1,4, Rafat Mm Al-Awad2.
Abstract
INTRODUCTION: Isotretinoin, a vitamin A-derived medication, is one of the effective treatments for severe acne. However, in a fraction of patients, this treatment causes significant adverse effects. Leptin is a pro-inflammatory cytokine that plays a role in apoptosis of adipose cells and sebaceous lipid metabolism. Thus, genetic polymorphisms in the leptin (LEP) gene may modulate the response to isotretinoin therapy. Here, we explore the contribution of rs7799039 polymorphism of the LEP gene in the adverse effects of the oral isotretinoin therapy among acne patients.Entities:
Keywords: acne; isotretinoin; leptin; polymorphism; side effects
Year: 2018 PMID: 29872305 PMCID: PMC5973407 DOI: 10.2147/TCRM.S165712
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Characteristics of acne patients of the current study (n = 200)
| Variable | Patients, n% |
|---|---|
| Age (years; mean ± SD) | 23.36 ± 6.449 |
| Body mass index (kg/m2; mean ± SD) | 24.07 ± 3.802 |
| Sex (male: female) | 20.5: 79.5 |
| Marital status, n (%) | |
| Single | 158 (79.0) |
| Married | 42 (21.0) |
| Smoking | |
| No | 179 (89.5) |
| Yes | 21 (10.5) |
| Most reported side effects, n (%) | |
| Arthralgia/myalgia | 155 (77.5) |
| Nosebleed | 159 (79.5) |
| Headache | 149 (74.5) |
Modulation of lipid profile and liver enzymes by isotretinoin therapy (n = 200)
| Parameter | Measure | Before isotretinoin therapy | After isotretinoin therapy |
|---|---|---|---|
| Lipid profile (mmol/L) | HDL | 1.41 ± 0.24 | 1.32 ± 0.32 |
| LDL | 2.33 ± 0.71 | 2.78 ± 0.76 | |
| TC | 4.141 ± 0.88 | 4.61 ± 0.97 | |
| TG | 0.99 ± 0.57 | 1.32 ± 0.77 | |
| Liver function enzymes (U/L) | AST | 18.61 ± 4.97 | 21.71 ± 9.84 |
| ALT | 15.71 ± 9.01 | 17.73 ± 12.30 |
Notes: Data expressed as mean ± standard deviation.
Significant difference (P < 0.01).
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
The impact of rs7799039 genotypes on biochemical parameters that are modulated by isotretinoin (n = 200)
| Parameter | Genotypes (mean ± SD)
| ||
|---|---|---|---|
| CC | AC | AA | |
| HDL (mmol/L) | |||
| Baseline | 1.30 ± 0.29 | 1.4 ± 0.27 | 1.37 ± 0.31 |
| After treatment | 1.26 ± 0.31 | 1.36 ± 0.28 | 1.33 ± 0.29 |
| % change | −9.54 ± 1.58 | −3.03 ± 1.77 | −9.54 ± 1.20 |
| LDL (mmol/L) | |||
| Baseline | 2.37 ± 0.61 | 2.30 ± 0.82 | 2.30 ± 0.62 |
| After treatment | 2.81 ± 0.70 | 2.80 ± 0.88 | 2.69 ± 0.55 |
| % change | 1.95 ± 2.08 | 2.73 ± 2.11 | 2.02 ± 1.96 |
| TC (mmol/L) | |||
| Baseline | 4.02 ± 0.85 | 4.24 ± 0.98 | 4.10 ± 0.70 |
| After treatment | 4.55 ± 0.97 | 4.67 ± 1.09 | 4.59 ± 0.63 |
| % change | 1.03 ± 1.29 | 1.44 ± 1.42 | 9.92 ± 1.25 |
| TG (mmol/L) | |||
| Baseline | 0.97 ± 0.55 | 1.04 ± 0.65 | 0.91 ± 0.40 |
| After treatment | 1.22 ± 0.71 | 1.45 ± 0.89 | 1.21 ± 0.50 |
| % change | 45.5 ± 116.9 | 40.6 ± 56.7 | 29.4 ± 44.4 |
| AST (U/L) | |||
| Baseline | 18.40 ± 4.12 | 19.46 ± 6.04 | 17.00 ± 2.73 |
| After treatment | 20.61 ± 6.05 | 23.40 ± 10.0 | 19.72 ± 4.75 |
| % change | 1.956 ± 3.70 | 1.88 ± 2.52 | 1.28 ± 3.72 |
| ALT (U/L) | |||
| Baseline | 15.56 ± 10.34 | 17.12 ± 9.35 | 12.68 ± 3.26 |
| After treatment | 16.9 ± 9.15 | 19.44 ± 9.85 | 15.14 ± 5.55 |
| % change | 17.41 ± 43.67 | 23.81 ± 50.69 | 14.07 ± 69.84 |
Notes:
CC genotype is significantly different from AC genotype.
A significant difference of CC genotype with AC genotype.
A significant difference of CC with other genotypes.
A significant difference of AC genotype with other genotypes.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.